baccaratcrystalball| Heplatinum Pharmaceuticals-B now rises more than 6% and enters into a licensing and option agreement with AstraZeneca for a new tumor-targeted therapy

Heplatinum Pharmaceuticals-B (02142) opened higher in early tradingbaccaratcrystalball, once rose 15%, the stock fell back slightly to a gain of 6%baccaratcrystalball.43%, currently quoted at HK$1.49, with a turnover of HK$8.0032 million.

Heplatinum Pharmaceuticals announced that Nona Biotech (Suzhou) Co., Ltd., a wholly-owned subsidiary of the company, has entered into a license and option agreement with AstraZeneca (AZN.US) for preclinical monoclonal antibodies used to create tumor-targeted therapies.